On July 28, 2025, CervoMed Inc. reported 32-week data results from its clinical trial of neflamapimod for patients with dementia, highlighting reductions in plasma levels of Glial Fibrillary Acidic Protein. This information includes findings from the trial's Extension Phase and is available on their website for investors and analysts.